SELLAS Life Sciences (SLS) Total Liabilities (2010 - 2026)
SELLAS Life Sciences (SLS) posted quarterly Total Liabilities of $6.8 million for Q1 2026, down 6.0% year-over-year from $7.2 million in Q1 2025, and down 9.49% quarter-over-quarter from $7.5 million in Q4 2025.
SELLAS Life Sciences (SLS) Total Liabilities (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Total Liabilities for 17 consecutive years, with $6.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 6.0% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $6.8 million (down 6.0% YoY), while the FY2025 annual figure was $7.5 million, down 25.01% from the prior year.
- Total Liabilities fell to $6.8 million in Q1 2026 per SLS's latest filing, from $7.5 million in the prior quarter.
- Across five years, Total Liabilities topped out at $17.4 million in Q1 2022 and bottomed at $5.9 million in Q3 2025.
- Historically, Total Liabilities has averaged $11.6 million across 5 years, with a median of $12.2 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 171.46% — and 2025, when it slumped 51.21%.
- SELLAS Life Sciences' Total Liabilities stood at $16.1 million in 2022, then dropped by 11.79% to $14.2 million in 2023, then declined by 29.79% to $10.0 million in 2024, then fell by 25.01% to $7.5 million in 2025, then declined by 9.49% to $6.8 million in 2026.
- Business Quant data shows SLS's Total Liabilities at $6.8 million in Q1 2026, $7.5 million in Q4 2025, and $5.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | SELLAS Life Sciences | 2.32 Bn | 2.18 Bn | - | 7.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.73 Mn |
| Mar 31, 2026 | 6.77 Mn |
| Dec 31, 2025 | 7.47 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 6.16 Mn |
| Mar 31, 2025 | 7.20 Mn |
| Dec 31, 2024 | 9.97 Mn |
| Sep 30, 2024 | 10.61 Mn |
| Jun 30, 2024 | 12.21 Mn |
| Mar 31, 2024 | 14.75 Mn |
| Dec 31, 2023 | 14.20 Mn |
| Sep 30, 2023 | 11.91 Mn |
| Jun 30, 2023 | 13.72 Mn |
| Mar 31, 2023 | 15.94 Mn |
| Dec 31, 2022 | 16.09 Mn |
| Sep 30, 2022 | 13.40 Mn |
| Jun 30, 2022 | 13.15 Mn |
| Mar 31, 2022 | 17.41 Mn |
| Dec 31, 2021 | 5.93 Mn |
| Sep 30, 2021 | 11.35 Mn |